New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:53 EDTCBMGCellular Biomedicine releases positive ReJoin Phase I/IIa six-month data
Cellular Biomedicine released the six-month follow-up data analysis of its Phase I/IIa clinical trial for its Rejoin human adipose-derived mesenchymal precursor cell, or haMPC, therapy for Knee Osteoarthritis, or KOA. The trial, conducted by Shanghai Renji Hospital, tested the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. The primary endpoints for this trial were safety and knee-related pain, stiffness and function measured using the Western Ontario and McMaster Universities osteoarthritis index questionnaire. The secondary endpoints were cartilage repair at six months, defined through the volume of the repair tissue measured with quantitative magnetic resonance imaging as well as NRS-11, SF-36 and KSCRS scores.
News For CBMG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 5, 2014
11:02 EDTCBMGCellular Biomedicine reports 48-week data from phase I/IIa ReJoin trial
Cellular Biomedicine released the 48-week follow-up data analysis of its Phase I/IIa clinical trial for Rejoin human adipose-derived mesenchymal progenitor cell regenerative therapy for Knee Osteoarthritis. The trial, conducted by Shanghai Renji Hospital, tested the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. The data analysis was presented at the 10th Annual World Stem Cell Summit and RegMed Capital Conference held in San Antonio, Texas. "We are very encouraged with the data from this trial. Patients have reported a decrease in pain and a significant improvement in mobility and flexibility, while the clinical data shows ReJoin regenerative medicine treatment to be safe. We are excited about the progress and look forward to publishing the interim data from the Phase IIb trial in the first quarter of 2015," commented CEO William Cao.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use